Physician profile
Barbara Page
NPI 1538517941
$3,229.11
in general payments reported to CMS, 2019-2025
14 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $1,153 · 2023: $583 · 2024: $223 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $720.50 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $692.64 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $447.14 | 2021-2025 | Rexulti |
| Corium, LLC | $435.71 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $315.74 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.50 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $114.66 | 2021-2022 | |
| Lundbeck LLC | $110.79 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $86.83 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $38.63 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $37.88 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.64 | 2022 | |
| Adlon Therapeutics L.P. | $31.88 | 2021 | |
| Eisai INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.